Finance entity
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 12 of these 20 stories. Against the same-window beat baseline of 17% negative, this entity's 0% share is less negative. markets accounts for 13 of the 20 tracked stories, while 1 other category carries the remainder.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 12 of these 20 stories. Against the same-window beat baseline of 17% negative, this entity's 0% share is less negative. markets accounts for 13 of the 20 tracked stories, while 1 other category carries the remainder. That works out to roughly 5 stories per week across a 28-day span. The busiest single day carried 4. Each story carries 2.1 original sources on average, compared with 2.2 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.7. Weiss Ratings appears in 20 tracked Finance stories published from August 13, 2026 through September 9, 2026.
Computed from the 20 stories linked to this entity, with beat comparisons drawn from all 528 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Weiss Ratings. Shared-story counts are live from our verified record — not editorial picks.
Eaton Shares Rise 2.8%
Shares trade as high as $430.25 and last at $422.2780, closing above the 50-day and 200-day moving averages.
Dividend payment
The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
Morgan Stanley and Weiss Ratings Turn Constructive
Morgan Stanley raises its Eaton target to $520 from $500 and Weiss Ratings upgrades the stock from hold to buy.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Ex-dividend date
Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
AECOM Reports Q2 Loss and Issues FY2026 Guidance
AECOM posted a Q2 loss of $0.50 per share on $3.59B revenue and guided FY2026 EPS to $3.95-$4.15, far below consensus.
Amentum Updates FY2026 Guidance
Amentum guided FY2026 EPS to $2.40-$2.50 and revenue to $13.8B-$14.0B, missing revenue consensus.
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
ZVIA reports Q2 results
Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Lucid Group shares fell 1.1% to $4.63 on September 8, 2026, trading 25% below its 50-day moving average of $6.17. With a consensus Reduce rating and a $9.22 price target, the stock's negative EPS and 3.0 debt-to-equity ratio pose significant downside risk for value and momentum investors.
Source: tickerreport.com · dailypolitical.com
Eaton's 2.8% climb to $422.28 reflects a cluster of price-target raises led by Morgan Stanley and RBC. For finance readers, the key tension is a 20-analyst Buy consensus versus a 42.96 P/E and 2.60 PEG that price in significant electrification growth.
Source: tickerreport.com · dailypolitical.com
Tuesday's midday tape lifted MARA 4.6% to $11.83 and Sterling Infrastructure 3.2% to $502.20, but the more important signal for investors is a multi-week pattern of analyst price-target cuts. MARA's consensus target of $18.78 implies large upside yet carries 5.32 beta and negative earnings; STRL's $690.33 target still sits 37% above its price but below prior $900-plus targets. Finance readers should weigh consensus 'Moderate Buy' labels against balance-sheet and technical risks.
Source: themarketsdaily.com · tickerreport.com
Kanzhun reported Q2 EPS of $0.33, beating by $0.01, but revenue of $353.05 million missed consensus by $1.58 million. With a $6.33 billion market cap, 15.14 P/E, and beta of 0.48, analysts see Moderate Buy with an average target of $18.67.
Source: Watch List News · Ticker Report
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
A Q2 13F filing shows Northwestern Mutual Wealth Management initiated a $106.97M RTX position and an $18.25M Cummins stake. Analysts are raising price targets on both names, reinforcing institutional conviction in industrial cyclicals.
Source: Watch List News · Bbns
Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
Keysight Technologies beat Q3 estimates and raised full-year EPS guidance to $11.46 on $7.1 billion revenue, yet shares sold off 5.5% on the news. The reaction highlights valuation concerns despite a forward P/E of about 30.
Source: MarketBeat · dailypolitical.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Silexion beat consensus by $16.03 with a ($5.17) EPS, yet shares fell to $0.42. With volume at 2x average, a 52-week high of $80, and Hold consensus, the microcap has shed nearly all value.
Institutional 13F data shows new accumulation in Chubb as small advisory firms added positions from Q4 2025 through Q2 2026. Analyst targets range from $301 to $386, while insider sales and 83.81% institutional ownership frame a mixed but liquid market for CB.
Source: Ticker Report · Daily Political
Safe Pro Group reported a quarterly EPS of -$0.15, one cent below consensus, but shares soared 37.7% on 21x average volume. The move pushed market cap to $128.89M even as negative net margin widened to 800.91%.
Source: MarketBeat · themarketsdaily.com
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Source: tickerreport.com · dailypolitical.com
Weiss Ratings is linked from 46 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
